This article reviews the patent literature on cyclic nucleotide phosphodiesterase inhibitors for the treatment of cardiovascular diseases such as thrombosis and atherosclerosis.
Answers are grounded in this paper and cite their sources.
Patent review signals active innovation in PDE inhibitors for thrombosis; leaves open clinical translation pending trials.
Cyclic nucleotide phosphodiesterases (PDEs) hydrolyse cyclic nucleotides to their inactive form (5' nucleotides), and thereby play an important role in cellular signalling mechanisms. These enzymes can be classed into seven families (or isozymes/isoenzymes) on the basis of their amino acid sequence, substrate specificity and sensitivity to pharmacological agents. This article reviews each PDE family in turn and analyses the patent literature in each area. Specific attention has been placed on those patents which disclose compounds reported to be useful for the treatment of cardiovascular diseases including thrombosis and atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Catherine Demoliou-Mason (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: